论文部分内容阅读
目的:研究合用rhG-CSF(基因重组-人粒细胞集落刺激因子)的小剂量HA方案治疗低增性急性粒细胞白血病(AML)的可行性。方法:回顾性分析合用rhG-CSF的小剂量HA方案治疗经FAB分型确诊的10例低增生性AML的疗效及可行性。结果:10例患者获CR 7例(M1 1例、M2 4例、M4 1例、M5 1例),PR 1例,NR 2例(M1 1例、M2 1例),CR率70%,有效率80%。结论:合用rhG-CSF的小剂量HA方案治疗低增生性AML的CR率达70%,有效率达80%,并缩短了骨髓抑制时间,减少了化疗并发症。
Objective: To investigate the feasibility of low-dose HA regimen combined with rhG-CSF (recombinant human-human granulocyte-colony stimulating factor) for the treatment of hypo-acute myeloid leukemia (AML). Methods: The efficacy and feasibility of 10 cases of low-proliferative AML confirmed by FAB typing were analyzed retrospectively. Results: CR was found in 10 patients (M1 1, M2 4, M4 1, M5 1), PR 1, NR 2 (M1 1, M2 1) Efficiency 80%. CONCLUSIONS: The low-dose HA regimen combined with rhG-CSF can treat 70% of patients with low-proliferative AML with an effective rate of 80%, shortening the time of myelosuppression and reducing the complications of chemotherapy.